Non-Nicotine Alkaloid Vapor Composition for Smoking Sensory Replication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing electronic nicotine delivery systems fail to provide a sensory experience similar to traditional tobacco smoking, leading to low compliance and ineffective smoking cessation.
Innovation Solution
Vaporizable alkaloid compositions comprising substituted pyridine compounds, solvents, and optional chemosensory irritants and flavoring agents, optimized to simulate the sensory experience of traditional tobacco smoking without nicotine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If electronic nicotine delivery systems use traditional nicotine-based formulations, then physiological dependence is maintained, but sensory experience does not replicate traditional smoking
Solution Approach 1:
The patent changes the chemical composition parameters by substituting nicotine with non-nicotine alkaloids (such as anabasine, nicotyrine, or other pyridine-containing compounds) while adjusting the sensory profile through additives. This parameter change maintains the sensory experience of traditional smoking without the harmful effects of nicotine, thereby improving both ease of operation (sensory similarity) and reliability (cessation effectiveness).
Solution Approach 2:
The invention uses composite formulations combining multiple components: non-nicotine alkaloids, flavoring agents, chemosensory irritants, and solvents (such as propylene glycol and glycerin). This composite approach creates a vaporizable liquid that replicates the complex sensory profile of tobacco smoke while eliminating nicotine, resolving the contradiction between sensory similarity and cessation effectiveness.
2Object-affected harmful factors
If vaporizable compositions are formulated without nicotine, then health benefits are improved, but sensory experience diverges from traditional smoking
Solution Approach 1:
The patent introduces intermediary substances including flavoring agents and chemosensory irritants that mediate the sensory experience. These additives compensate for the absence of nicotine by providing similar sensory effects (throat hit, mouthfeel, aroma) through alternative chemical mechanisms, thereby maintaining ease of operation while eliminating harmful nicotine-related factors.
Solution Approach 2:
The formulation changes key parameters by replacing nicotine with alternative alkaloids and adjusting the concentration and type of chemosensory irritants and flavoring agents. This parameter optimization maintains sensory similarity to traditional smoking while eliminating nicotine, thus resolving the contradiction between harm reduction and sensory experience.
3Device complexity
If existing vaporizable liquids are used, then device simplicity is maintained, but compliance with cessation programs is low
Solution Approach 1:
The patent optimizes the compositional parameters of the vaporizable liquid to enhance user experience and compliance. By carefully selecting non-nicotine alkaloids, flavoring agents, and chemosensory irritants in specific concentrations, the formulation creates a more satisfying sensory experience that encourages continued use and compliance with cessation programs, while maintaining device simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides a viable alternative to tobacco smoking, enhancing compliance with smoking cessation programs by replicating the sensory experience of traditional smoking.
Implementation Method 1
vaporizable alkaloid compositions comprising at least one substituted pyridine compound, or salt thereof, or mixed salt thereof, and at least one solvent
Data Source
AI summary
In various embodiments of the present disclosure, vaporizable alkaloid compositions comprising a substituted pyridine compound of Formula (I) and entirely absent nicotine are described that are capable of forming an inhalable vapor when dispensed from an electronic device such as an e-cigarette. A series of such vaporizable alkaloid compositions having decreasing (w/v) amounts of substituted pyridine compound are provided as part of a smoking cessation program.


